Brain Death and Organ Donation

Quick Answer

Brain death is the irreversible cessation of ALL brain function, including the brainstem, representing the legal and medical definition of death in most jurisdictions. Determination requires exclusion of confounders (hypothermia below 35°C, drugs, metabolic derangements, shock), clinical examination by two qualified doctors demonstrating absent brainstem reflexes, and a positive apnea test (PaCO2 greater than 60 mmHg or greater than 20 mmHg rise without respiratory effort). Ancillary tests (EEG, TCD, CTA, scintigraphy) are indicated when clinical examination cannot be completed. Once brain death is confirmed, deceased donor management focuses on physiologic optimization using the "Rule of 100s" (MAP greater than 65-80 mmHg, HR greater than 60 bpm, UO 0.5-3 mL/kg/h, Hb greater than 70-100 g/L, PaO2 greater than 100 mmHg), hormone replacement therapy (T3, vasopressin, methylprednisolone), and lung-protective ventilation to maximize organ viability for transplantation.[1,2,3]

---

CICM Exam Focus

Second Part Written Exam

Brain death and organ donation appear in multiple CICM exam formats:

Common SAQ Topics

• "Describe the clinical testing for brain death determination"
• "Outline the apnea test protocol"
• "Discuss the physiologic consequences of brain death"
• "Compare donation after brain death (DBD) vs donation after circulatory death (DCD)"
• "Outline the management of a potential organ donor"

Viva Scenarios

• Brain death determination in a patient with severe TBI
• Managing cardiovascular instability in a potential organ donor
• Family meeting discussing organ donation
• Apnea test complications and troubleshooting
• Confounders preventing brain death testing

---

Key Points

Clinical

• Brain death = irreversible cessation of ALL brain function including brainstem
• Requires exclusion of confounders: hypothermia (below 35°C), sedatives, paralytics, severe metabolic/endocrine derangements, shock
• Clinical examination by two qualified doctors (separate examinations)
• Brainstem reflexes must ALL be absent: pupillary, corneal, oculocephalic, oculovestibular, gag, cough
• Apnea test: PaCO2 greater than 60 mmHg OR greater than 20 mmHg rise from baseline without respiratory effort
• Ancillary tests indicated when clinical exam cannot be completed: EEG, TCD, CTA/MRA, scintigraphy

Pathophysiology

• Supratentorial herniation → brainstem compression → medullary ischemia
• Loss of hypothalamic-pituitary function → diabetes insipidus, thyroid dysfunction, cortisol deficiency
• Loss of sympathetic outflow → cardiovascular collapse, hypothermia
• Cytokine storm and inflammatory response → multi-organ dysfunction

Donor Management

• Rule of 100s: MAP 65-80 mmHg, HR greater than 60 bpm, UO 0.5-3 mL/kg/h, Hb greater than 70-100 g/L, PaO2 greater than 100 mmHg, glucose below 10 mmol/L
• Hormone replacement: T3 (or T4), vasopressin, methylprednisolone
• Lung-protective ventilation: Tidal volume 6-8 mL/kg IBW, PEEP 8-10 cmH2O, plateau pressure below 30 cmH2O
• Fluid resuscitation: Target euvolaemia, avoid excessive crystalloid
• Temperature: Maintain greater than 35°C (active warming if needed)

Donation Pathways

• DBD (Donation after Brain Death): Brain death declared → organ retrieval
• DCD (Donation after Circulatory Death): WLST → circulatory arrest (5 min asystole) → organ retrieval
• Maastricht Classification: Categories I-V (uncontrolled vs controlled DCD)

---

Epidemiology

Incidence

Brain death accounts for approximately 1-2% of all deaths in developed countries, with the majority occurring in intensive care units following severe traumatic brain injury, intracranial hemorrhage, or hypoxic-ischemic injury.[4]

Organ Donation Rates

In Australia and New Zealand, the organ donation rate has improved significantly over the past decade:

• Australia (2022): 23.8 donors per million population (dpmp)[5]
• New Zealand (2022): 16.4 dpmp[5]
• Spain (world leader): greater than 40 dpmp[6]

Approximately 60-70% of deceased organ donors are donation after brain death (DBD), while 30-40% are donation after circulatory death (DCD).[5]

Consent Rates

Family consent rates for organ donation vary by jurisdiction and are influenced by cultural, religious, and educational factors:

• Australia: ~70% family consent rate (2022)[5]
• New Zealand: ~65% family consent rate (2022)[5]
• Opt-out systems (e.g., Spain, UK): Higher donation rates due to presumed consent[6]

---

Pathophysiology

Brain Herniation and Brainstem Death

Brain death results from severe intracranial hypertension exceeding cerebral perfusion pressure, leading to global cerebral ischemia and brainstem herniation.[7]

Stages of Herniation

1. Supratentorial mass effect → uncal or central herniation
2. Tentorial herniation → midbrain compression → loss of oculomotor function
3. Foramen magnum herniation → medullary compression → loss of respiratory drive
4. Global cerebral ischemia → cessation of cerebral blood flow → irreversible neuronal death

Cerebral Circulatory Arrest

As intracranial pressure (ICP) exceeds mean arterial pressure (MAP), cerebral perfusion pressure (CPP = MAP - ICP) approaches zero, resulting in cessation of cerebral blood flow. This is demonstrable on ancillary tests such as cerebral angiography (no intracranial filling beyond the carotid terminus) or transcranial Doppler (reverberating flow or absent diastolic flow).[8]

Systemic Effects of Brain Death

Cardiovascular

• Initial catecholamine surge (Cushing reflex) → severe hypertension, tachycardia → myocardial stunning
• Loss of sympathetic tone → profound hypotension, bradycardia
• Myocardial dysfunction → reduced ejection fraction (30-50% of brain-dead donors)[9]

Endocrine

Loss of hypothalamic-pituitary function results in multiple hormonal deficiencies:[10]

Pulmonary

• Neurogenic pulmonary edema (10-20% of brain-dead patients)[11]
• Aspiration pneumonitis (common in preceding injury)
• Ventilator-associated complications (barotrauma, VAP)

Renal

• Pre-renal acute kidney injury (hypotension, DI-induced hypovolemia)
• Acute tubular necrosis (prolonged hypoperfusion)

Metabolic

• Hypothermia (below 35°C in 50% of brain-dead donors)[12]
• Coagulopathy (release of tissue thromboplastin, DIC)
• Electrolyte disturbances (hypernatremia from DI, hypocalcemia, hypomagnesemia)

Inflammatory

• Cytokine storm (TNF-α, IL-6, IL-8) → systemic inflammation → multi-organ dysfunction[13]

---

Clinical Presentation

Prerequisites for Brain Death Testing

Before proceeding with brain death determination, the following prerequisites must be met:[1,2]

1. Clinical Context

• Established cause of catastrophic brain injury compatible with brain death
• Neuroimaging demonstrating severe injury (CT or MRI)
• Irreversible injury: No possibility of recovery

2. Exclusion of Confounders

3. Absence of Severe Acid-Base Disturbance

• pH ≥7.20 (some guidelines ≥7.30)[2]

4. Adequate Oxygenation

• PaO2 ≥60 mmHg (8 kPa) on FiO2 ≥0.4[2]

Clinical Examination

Brain death determination requires documentation of absent motor response and absent brainstem reflexes on examination by two qualified doctors (intensivists, neurologists, or neurosurgeons) on separate occasions.[1,2]

Motor Response

• Supraorbital pressure: No grimacing, no motor response
• Peripheral painful stimuli: May elicit spinal reflexes (acceptable), but NO purposeful response

Brainstem Reflexes

All of the following reflexes must be absent:[1,2]

Important Considerations

• Oculocephalic reflex: Contraindicated in suspected cervical spine injury (use oculovestibular instead)
• Oculovestibular reflex: Ensure tympanic membrane is intact; wait 5 minutes between ears; elevate head 30° (to position horizontal semicircular canal vertically)
• Spinal reflexes: May persist (e.g., triple flexion, deep tendon reflexes) and do NOT preclude brain death diagnosis[15]

Apnea Test

The apnea test confirms the absence of respiratory drive mediated by the medullary respiratory center. It is the definitive test for brainstem function.[1,2]

Apnea Test Protocol

1. Pre-oxygenation

   • FiO2 1.0 for 10 minutes
   • Adjust ventilation to achieve normocapnia (PaCO2 35-45 mmHg)
   • Ensure hemodynamic stability (SBP ≥90 mmHg)

2. Baseline Blood Gas

   • Confirm PaCO2 35-45 mmHg, PaO2 ≥200 mmHg

3. Disconnect Ventilator

   • Remove from ventilator
   • Provide apneic oxygenation: O2 insufflation at 6 L/min via catheter placed at the carina (via endotracheal tube)

4. Observation Period

   • Observe for respiratory movements (chest or abdominal wall excursion)
   • Duration: 8-10 minutes (or until PaCO2 ≥60 mmHg)

5. Repeat Blood Gas

   • After 8-10 minutes, obtain arterial blood gas

6. Interpretation

   • Positive test (consistent with brain death): No respiratory effort despite PaCO2 ≥60 mmHg OR ≥20 mmHg rise from baseline
   • Negative test (inconsistent with brain death): Respiratory effort observed
   • Indeterminate: Test aborted due to instability (proceed to ancillary test)

Complications of Apnea Test

• Hypotension (20-30% of tests)[16]
• Cardiac arrhythmias (bradycardia, asystole)
• Hypoxemia (rare if adequate pre-oxygenation)
• Pneumothorax (rare)

Contraindications to Apnea Test

• Severe hemodynamic instability (refractory hypotension, high-dose vasopressors)
• Severe hypoxemia (unable to achieve PaO2 ≥200 mmHg)
• Severe pre-existing respiratory disease (e.g., COPD with baseline hypercapnia)

In these cases, proceed directly to ancillary testing.[1]

---

Ancillary Tests

Ancillary tests are indicated when:[1,2]

• Clinical examination cannot be completed (e.g., severe facial trauma, severe eye injury)
• Apnea test cannot be performed (e.g., hemodynamic instability, severe hypoxemia)
• Apnea test is indeterminate (e.g., inability to achieve target PaCO2)
• Legal requirement in some jurisdictions (e.g., Germany, Italy)

Electroencephalography (EEG)

• Finding: Electrocerebral silence (ECS) or electrocerebral inactivity
  • No electrical activity greater than 2 microvolts at high sensitivity (2 µV/mm)
  • Recording duration ≥30 minutes
  • Standard 8-16 channel recording
• Limitations: Susceptible to artifacts (ICU equipment, muscle activity), pharmacologic suppression (barbiturates, benzodiazepines)[17]
• Sensitivity/Specificity: High specificity (~95%), but sensitivity limited by technical factors[18]

Transcranial Doppler (TCD)

• Finding: Absent cerebral blood flow
  • Small systolic spikes without diastolic flow
  • "Reverberating (oscillating) flow: Forward flow in systole, retrograde flow in diastole"
  • Absent signal (if previously present)
• Technique: Insonation of middle cerebral artery (MCA) and basilar artery (BA) via temporal and suboccipital windows
• Limitations: 10-20% of patients lack adequate bone windows (temporal bone too thick)[19]
• Sensitivity/Specificity: Sensitivity 90%, specificity 98% (when adequate windows obtained)[20]

Cerebral Angiography (4-Vessel)

• Finding: No intracranial filling beyond the carotid terminus or circle of Willis
  • Contrast "stops" at the skull base
  • External carotid circulation may be preserved
• Technique: Catheter angiography with injection of contrast into bilateral carotid and vertebral arteries
• Limitations: Invasive, requires transport, contrast exposure, radiation
• Sensitivity/Specificity: Considered the gold standard (sensitivity ~100%, specificity ~100%)[21]

CT Angiography (CTA)

• Finding: Absence of intracranial blood flow (no opacification of intracranial arteries beyond carotid terminus)
• Technique: Contrast-enhanced CT from aortic arch to vertex
• Advantages: Non-invasive, rapid, no patient transport (if ICU CT scanner available)
• Sensitivity/Specificity: Sensitivity 85-90%, specificity 98-100%[22]

MR Angiography (MRA)

• Finding: Absent intracranial flow
• Technique: Time-of-flight or contrast-enhanced MRA
• Limitations: Logistical challenges (MRI compatibility, patient transport, monitoring)
• Sensitivity/Specificity: Comparable to CTA[23]

Cerebral Scintigraphy (Nuclear Medicine)

• Finding: "Hollow skull sign" or "empty light bulb sign"
  • No uptake of radiotracer in cerebral hemispheres or cerebellum
  • Activity only in scalp
• Technique: Intravenous injection of Technetium-99m HMPAO or ECD
• Advantages: Unaffected by sedatives, can be performed at bedside (portable gamma camera)
• Sensitivity/Specificity: Sensitivity 94%, specificity 100%[24]

Comparison of Ancillary Tests

---

Determination of Death

Legal and Ethical Framework

In Australia and New Zealand, brain death is legally recognized as death, equivalent to circulatory death. The time of death is documented as the time when both of the following are met:[2]

1. All clinical criteria are satisfied (including apnea test or ancillary test)
2. Two qualified doctors have independently confirmed the findings

Qualified Doctors

• Senior medical practitioners with appropriate training (intensivists, neurologists, neurosurgeons)
• Independent assessments (separate examinations, although timing may vary by jurisdiction)
• At least one examiner should be a consultant-level physician[2]

Documentation

Complete documentation must include:[2]

• Date and time of examinations
• Exclusion of confounders (temperature, drugs, metabolic status)
• Clinical findings (all brainstem reflexes)
• Apnea test results (baseline and final PaCO2, presence/absence of respiratory effort)
• Ancillary test results (if performed)
• Time of death: When final determination completed
• Names and signatures of both examining doctors

Family Communication

Effective communication with the family is critical and should:[25]

• Separate the discussion of brain death determination from organ donation (avoid perception of conflict of interest)
• Explain brain death in clear, non-technical language ("the brain has stopped working and will never recover")
• Allow time for comprehension and questions
• Provide culturally sensitive support (interpreter, spiritual care)
• Involve organ donation coordinators (dedicated trained personnel, NOT the treating intensivist) for donation discussions

---

Organ Donation

Donation Pathways

Donation After Brain Death (DBD)

• Definition: Organ retrieval following formal brain death determination
• Advantages:
  • Warm ischemia time = 0 (organs perfused until cross-clamp)
  • Better organ function (especially liver, pancreas, small bowel)
  • Allows time for family, donor optimization, tissue typing
• Disadvantages: Requires brain death determination (prerequisites may not be met)

Donation After Circulatory Death (DCD)

• Definition: Organ retrieval following withdrawal of life-sustaining treatment (WLST) and circulatory arrest
• Maastricht Classification:[26]

• Most DCD donors: Category III (controlled DCD following WLST in ICU)
• Warm ischemia time: Begins at circulatory arrest (SBP below 50 mmHg for 5 minutes) or cessation of mechanical support
• Mandatory "hands-off" period: 5 minutes of asystole (Australia/NZ)[27]
• Organs suitable for DCD: Kidneys, liver, lungs, pancreas (heart in selected programs)
• Outcomes: Comparable long-term graft survival to DBD for kidneys and liver[28]

Absolute Contraindications to Donation

• Active malignancy (except primary brain tumors, non-melanoma skin cancer)
• HIV infection (except donor-to-HIV+ recipient programs)
• Active tuberculosis (untreated)
• Creutzfeldt-Jakob disease (CJD) or prion disease
• Rabies
• Active sepsis with positive blood cultures (organism-dependent)

Relative Contraindications

• Age (older donors: acceptable for kidneys, liver; assess organ-specific function)
• Hepatitis B/C (acceptable for HBV/HCV+ recipients, or with antiviral prophylaxis)
• Bacterial meningitis (acceptable if treated, organism-sensitive, negative blood cultures)
• Chronic kidney disease (CKD 3-4: may use for dual kidney transplant)
• Diabetes, hypertension (assess end-organ damage)

---

Deceased Donor Management

The goal of donor management is to optimize physiologic function to maximize the number and quality of organs available for transplantation. Brain-dead donors experience profound physiologic derangements that must be actively corrected.[3]

Rule of 100s (Donor Management Goals)

The "Rule of 100s" is a mnemonic for donor management targets:[29]

Cardiovascular Management

Hemodynamic Optimization

1. Fluid resuscitation

   • Target euvolaemia (CVP 6-10 mmHg, or dynamic measures if available)
   • Use crystalloid (balanced solutions preferred) initially
   • Avoid excessive fluid (pulmonary edema risk)
   • Consider colloid (albumin) if large fluid deficits

2. Vasopressor/Inotrope Support

   • Vasopressin: First-line agent (see Hormone Replacement)
     • Dose: 0.5-4 units/h infusion (or 1 unit bolus followed by 0.5-2 units/h)
     • Replaces endogenous ADH deficiency
     • Reduces catecholamine requirements[30]
   • Noradrenaline: Second-line vasopressor if MAP inadequate on vasopressin
     • Dose: 0.01-0.5 mcg/kg/min
   • Dobutamine or adrenaline: If cardiac dysfunction (low cardiac output despite adequate filling)
     • Dose: 2-10 mcg/kg/min
   • Target: Minimize high-dose catecholamines (associated with worse graft outcomes)[31]

3. Arrhythmia Management

   • Bradycardia (HR below 60): Rarely hemodynamically significant; if problematic, consider adrenaline infusion or temporary pacing
   • Tachyarrhythmias: Correct electrolytes (K+, Mg2+), treat ischemia, consider beta-blockers or amiodarone

Echocardiography

• Baseline TTE or TEE to assess:
  • LV systolic function (EF)
  • Regional wall motion abnormalities (neurogenic myocardial stunning)
  • Valvular function
  • Intravascular volume status
• Repeat if hemodynamic deterioration

Respiratory Management

Lung-Protective Ventilation Strategy[32]

Airway Management

• Tracheal suctioning: Regular suctioning to clear secretions
• Ventilator-associated pneumonia (VAP) prevention: Head-up 30°, oral care, subglottic suctioning
• Bronchoscopy: Consider if lobar collapse or mucus plugging

Oxygenation Targets

• PaO2 ≥100 mmHg (13 kPa) on FiO2 ≤0.4
• PaO2/FiO2 ratio ≥300: Required for lung donation in most programs

Endocrine and Metabolic Management

Hormone Replacement Therapy

Hormone replacement is controversial but widely practiced. Evidence suggests benefit in hemodynamic stabilization and organ function.[10,33]

ANZICS/TSANZ Recommendations (2018):[34]

• Methylprednisolone: Recommended (15 mg/kg IV once)
• Vasopressin: Recommended for DI and as vasopressor
• T3/T4: Suggested (but evidence is mixed)

Diabetes Insipidus (DI)

DI occurs in 60-80% of brain-dead donors due to loss of ADH secretion.[35]

Diagnosis:

• Urine output greater than 4 mL/kg/h (or greater than 300 mL/h)
• Urine specific gravity below 1.005
• Serum sodium rising (greater than 145 mmol/L)
• Serum osmolality greater than 300 mOsm/kg, urine osmolality below 200 mOsm/kg

Management:

1. Vasopressin infusion: 0.5-4 units/h (titrate to UO 0.5-3 mL/kg/h)
2. Desmopressin (DDAVP): Alternative (1-4 mcg IV q6-12h)
3. Fluid replacement: Replace urinary losses with hypotonic fluid (0.45% saline or dextrose 5%)
4. Monitor electrolytes: Frequent sodium, osmolality checks (q2-4h)

Hypernatremia

• Target: Sodium 130-150 mmol/L
• Correction: Gradual (avoid rapid correction if chronic)
  • Free water replacement (via NG tube or IV 5% dextrose)
  • Treat underlying DI (vasopressin)

Glycemic Control

• Target: Glucose 4-10 mmol/L (or below 10 mmol/L)
• Method: IV insulin infusion (as per institutional protocol)
• Rationale: Hyperglycemia associated with worse graft outcomes (especially pancreas)[36]

Hematologic Management

Transfusion Thresholds

• Hemoglobin: Maintain ≥70-100 g/L (transfuse if below 70 g/L; some centers target greater than 80 g/L)
• Platelets: Maintain ≥50 x 10^9/L (if active bleeding or pre-operative)
• Coagulation: Correct INR greater than 2 (FFP, prothrombin complex concentrate) or fibrinogen below 1.5 g/L (cryoprecipitate)

Disseminated Intravascular Coagulation (DIC)

• Monitoring: Serial coagulation studies, D-dimer, fibrinogen
• Treatment: Supportive (FFP, cryoprecipitate, platelets as needed)

Temperature Management

• Target: Core temperature ≥35-36°C
• Methods:
  • External warming (forced-air warming blanket, e.g., Bair Hugger)
  • Warmed IV fluids
  • Increased ambient temperature
• Rationale: Hypothermia causes coagulopathy, arrhythmias, impaired organ function

Renal Management

• Urine output: Target 0.5-3 mL/kg/h
• Avoid nephrotoxins: Minimize aminoglycosides, NSAIDs, contrast (if possible)
• Fluid balance: Maintain euvolaemia (avoid both hypovolemia and fluid overload)
• Diuretics: Avoid if possible (hypovolemia risk); if oliguric despite adequate filling, consider low-dose furosemide

Infection Control

• Antibiotics: Continue if infection present; obtain cultures (blood, sputum, urine)
• Surveillance cultures: Many programs perform routine cultures
• Infection: NOT an absolute contraindication to donation (organism-dependent; discuss with transplant team)

Nutrition

• Enteral nutrition: May continue if already established (gastric protection)
• Parenteral nutrition: Not required (short duration to organ retrieval)

---

ANZICS Donor Management Bundle

The Australian and New Zealand Intensive Care Society (ANZICS) endorses a donor management bundle to standardize and optimize donor care:[34]

1. Hemodynamic management: MAP ≥65 mmHg (vasopressin first-line)
2. Lung-protective ventilation: Tidal volume 6-8 mL/kg IBW, PEEP 8-10 cmH2O
3. Hormone replacement: Methylprednisolone 15 mg/kg IV (once)
4. Diabetes insipidus management: Vasopressin or DDAVP
5. Glycemic control: Target glucose below 10 mmol/L
6. Temperature management: Core temperature ≥35°C

Implementation of donor management bundles has been associated with increased organ yield and improved graft function.[3,37]

---

Special Populations

Paediatric Brain Death

• Similar principles to adult brain death, but with age-specific considerations:[38]
• Observation period: Longer periods recommended for neonates and infants (24-48 hours between examinations for term newborns below 7 days; 12-24 hours for infants 7 days to 2 months)
• Apnea test: PaCO2 target may differ (≥60 mmHg or ≥20 mmHg rise, similar to adults, but shorter observation period may be used with documented PaCO2 rise)
• Ancillary tests: Lower threshold for use in very young children

Donation After Circulatory Death (DCD)

Controlled DCD (Maastricht III)

Process:[27]

1. Decision for WLST: Made independently of organ donation
2. Family consent: Organ donation discussed by trained coordinators
3. Pre-mortem interventions (if consented):
   • Heparinization (10,000-30,000 units IV)
   • Vascular access (femoral arterial and venous cannulae)
   • Pre-oxygenation
4. WLST: In operating room or ICU (jurisdiction-dependent)
5. Circulatory arrest: SBP below 50 mmHg for 5 minutes OR asystole for 5 minutes
6. Declaration of death: By independent physician (not retrieval team)
7. Mandatory "hands-off" period: 5 minutes (Australia/NZ)
8. Organ retrieval: Rapid cannulation and cold perfusion

Warm Ischemia Time:

• Functional warm ischemia: From SBP below 50 mmHg to cold perfusion
• Total warm ischemia: From WLST to cold perfusion
• Target: Minimize (ideally below 30 minutes for kidneys, below 20 minutes for liver)

Exclusion Criteria:

• Prolonged time to circulatory arrest (greater than 90-120 minutes from WLST)
• Unexpected recovery (patient does not die within expected timeframe)

---

Complications of Brain Death and Donor Management

---

Prognosis and Outcomes

Brain Death

• Irreversible: Once brain death is confirmed, recovery is impossible (by definition)
• Somatic survival: Without organ donation, cardiovascular collapse typically occurs within 24-72 hours despite maximal support (up to 1 week in rare cases)[40]

Organ Transplantation Outcomes (DBD)

Deceased donor transplantation outcomes have improved significantly over the past decades:[41]

Factors Affecting Graft Outcomes

• Donor age: Older donors (greater than 60 years) associated with reduced graft survival (especially heart, lung, pancreas)
• Donor management: Optimal physiologic management improves graft function[3,37]
• Warm ischemia time: Critical for DCD (especially liver, kidneys)
• Cold ischemia time: Prolonged cold ischemia reduces graft survival
• Recipient factors: Age, comorbidities, immunologic matching, immunosuppression adherence

---

CICM SAQ Practice Questions

SAQ 1: Brain Death Clinical Testing

Question: Outline the clinical examination required for the determination of brain death in an adult patient. (10 marks)

Model Answer:

Prerequisites (2 marks):

• Established cause of catastrophic brain injury with neuroimaging confirmation (1)
• Exclusion of confounders: core temperature ≥35°C, absence of sedative/paralytic drugs (5 half-lives washout or undetectable levels), absence of severe metabolic/endocrine disturbances, SBP ≥90 mmHg, pH ≥7.20 (1)

Motor Response (1 mark):

• Absent motor response to supraorbital pressure; no purposeful movement to painful stimuli (spinal reflexes acceptable) (1)

Brainstem Reflexes (5 marks):

• Pupillary light reflex (CN II, III): Fixed, mid-position or dilated pupils (4-9 mm), no response to bright light (1)
• Corneal reflex (CN V, VII): No blink to corneal stimulation (0.5)
• Oculocephalic reflex (CN III, VI, VIII): Eyes move with head (no deviation); contraindicated if cervical spine injury (0.5)
• Oculovestibular reflex (CN III, VI, VIII): No eye movement to 50 mL ice-cold water in ear canal; wait 5 minutes between ears (1)
• Gag reflex (CN IX, X): No response to posterior pharyngeal stimulation (0.5)
• Cough reflex (CN X): No cough to tracheal suctioning to carina (0.5)

Apnea Test (2 marks):

• Pre-oxygenate with FiO2 1.0, disconnect ventilator, provide apneic oxygenation (O2 6 L/min at carina); observe for respiratory effort for 8-10 minutes or until PaCO2 ≥60 mmHg (1)
• Positive test: No respiratory effort despite PaCO2 ≥60 mmHg or ≥20 mmHg rise from baseline (1)

---

SAQ 2: Apnea Test Protocol

Question: Describe the apnea test for brain death determination, including the protocol, interpretation, and potential complications. (10 marks)

Model Answer:

Pre-Test Preparation (3 marks):

• Pre-oxygenate with FiO2 1.0 for 10 minutes (0.5)
• Adjust ventilation to achieve normocapnia (PaCO2 35-45 mmHg) (0.5)
• Ensure hemodynamic stability (SBP ≥90 mmHg) (0.5)
• Baseline arterial blood gas confirming PaCO2 35-45 mmHg and PaO2 ≥200 mmHg (0.5)
• Disconnect from ventilator (0.5)
• Provide apneic oxygenation: O2 insufflation at 6 L/min via catheter at the carina (via ETT) (0.5)

Observation (2 marks):

• Observe for respiratory movements (chest or abdominal wall excursion) for 8-10 minutes (1)
• Repeat arterial blood gas after 8-10 minutes (1)

Interpretation (2 marks):

• Positive test (consistent with brain death): No respiratory effort despite PaCO2 ≥60 mmHg OR ≥20 mmHg rise from baseline (1)
• Negative test: Respiratory effort observed (inconsistent with brain death) (0.5)
• Indeterminate: Test aborted due to hemodynamic instability (proceed to ancillary test) (0.5)

Complications (2 marks):

• Hypotension (20-30% of tests) (0.5)
• Cardiac arrhythmias (bradycardia, asystole) (0.5)
• Hypoxemia (rare if adequate pre-oxygenation) (0.5)
• Pneumothorax (rare) (0.5)

Contraindications (1 mark):

• Severe hemodynamic instability, severe hypoxemia (unable to achieve PaO2 ≥200 mmHg), severe pre-existing respiratory disease (e.g., COPD with baseline hypercapnia); in these cases, proceed directly to ancillary testing (1)

---

SAQ 3: Deceased Donor Management

Question: Outline the management of a potential deceased organ donor after brain death has been confirmed. (10 marks)

Model Answer:

Hemodynamic Management (3 marks):

• Targets: MAP ≥65-80 mmHg, HR 60-120 bpm, urine output 0.5-3 mL/kg/h (1)
• Fluid resuscitation: Crystalloid (balanced solutions) to achieve euvolaemia (CVP 6-10 mmHg); avoid excessive fluid (0.5)
• Vasopressin: First-line vasopressor (0.5-4 units/h); replaces ADH deficiency, reduces catecholamine requirements (1)
• Noradrenaline: Second-line if MAP inadequate on vasopressin (0.01-0.5 mcg/kg/min) (0.5)

Respiratory Management (2 marks):

• Lung-protective ventilation: Tidal volume 6-8 mL/kg IBW, PEEP 8-10 cmH2O, plateau pressure below 30 cmH2O, FiO2 lowest to achieve PaO2 greater than 100 mmHg (1)
• Target: PaO2 ≥100 mmHg on FiO2 ≤0.4, PaO2/FiO2 ratio ≥300 for lung donation (1)

Hormone Replacement (2 marks):

• Methylprednisolone: 15 mg/kg IV once (up to 1 g); anti-inflammatory, improves lung function (0.5)
• Vasopressin: 0.5-4 units/h infusion; replaces ADH, vasoconstrictor (0.5)
• Triiodothyronine (T3): 4 mcg IV bolus, then 3 mcg/h infusion; improves cardiac contractility (0.5)
• Insulin: Variable-rate IV infusion to target glucose 4-10 mmol/L (0.5)

Diabetes Insipidus Management (1.5 marks):

• Diagnosis: Urine output greater than 4 mL/kg/h, urine specific gravity below 1.005, rising serum sodium greater than 145 mmol/L (0.5)
• Treatment: Vasopressin infusion 0.5-4 units/h (or DDAVP 1-4 mcg IV q6-12h); titrate to UO 0.5-3 mL/kg/h (0.5)
• Fluid replacement: Hypotonic fluid (0.45% saline or 5% dextrose) to replace urinary losses (0.5)

Temperature Management (0.5 marks):

• Maintain core temperature ≥35-36°C; active warming (forced-air warming blanket, warmed IV fluids) (0.5)

Hematologic Management (0.5 marks):

• Transfuse to maintain hemoglobin ≥70-100 g/L; correct coagulopathy (INR greater than 2, fibrinogen below 1.5 g/L, platelets below 50 x 10^9/L) (0.5)

Monitoring (0.5 marks):

• Arterial line, central venous access, urine output, serial ABGs, electrolytes (q2-4h), echocardiography (baseline and if deterioration) (0.5)

---

SAQ 4: DBD vs DCD

Question: Compare donation after brain death (DBD) with donation after circulatory death (DCD). (10 marks)

Model Answer:

Donation After Brain Death (DBD) (4 marks):

• Definition: Organ retrieval following formal brain death determination (1)
• Process: Brain death confirmed → donor optimization → organ retrieval in operating room (0.5)
• Warm ischemia time: Zero (organs remain perfused until cross-clamp) (0.5)
• Advantages: Better organ function (especially liver, pancreas, small bowel); allows time for family discussions, donor optimization, tissue typing (1)
• Organs: All organs (heart, lungs, liver, kidneys, pancreas, small bowel, corneas, tissues) (0.5)
• Proportion: ~60-70% of deceased donors in Australia/NZ (0.5)

Donation After Circulatory Death (DCD) (4 marks):

• Definition: Organ retrieval following withdrawal of life-sustaining treatment (WLST) and circulatory arrest (1)
• Process: WLST → circulatory arrest (SBP below 50 mmHg for 5 min or asystole for 5 min) → declaration of death → 5-minute "hands-off" period → organ retrieval (1)
• Warm ischemia time: Begins at circulatory arrest; must be minimized (ideally below 30 min for kidneys, below 20 min for liver) (0.5)
• Maastricht Category III: Controlled DCD (most common); awaiting cardiac arrest after WLST in ICU (0.5)
• Organs: Kidneys, liver, lungs, pancreas (heart in selected programs); NOT suitable for small bowel (0.5)
• Proportion: ~30-40% of deceased donors in Australia/NZ (0.5)

Comparison (2 marks):

• Outcomes: Comparable long-term graft survival for kidneys and liver (DCD vs DBD) (0.5)
• DCD limitations: Warm ischemia exposure (higher delayed graft function rate for kidneys), more limited organ suitability (0.5)
• Ethical considerations: DCD does not require brain death determination; WLST decision made independently of donation (0.5)
• Logistical: DCD requires rapid coordination (time-sensitive); may occur in ICU or OR depending on jurisdiction (0.5)

---

CICM Viva Scenarios

Viva 1: Brain Death Determination in Severe TBI

Scenario: A 28-year-old male was admitted to ICU 48 hours ago following a severe traumatic brain injury (fall from height). He has been intubated and ventilated, sedated with propofol and fentanyl (ceased 24 hours ago), and has received rocuronium (last dose 8 hours ago). CT brain shows diffuse cerebral edema with effacement of basal cisterns and loss of grey-white differentiation. ICP monitoring shows sustained ICP greater than 40 mmHg despite maximal medical therapy. The neurosurgical team does not believe further intervention is warranted. The family asks if he is "brain dead."

Examiner Questions:

1. What are the prerequisites for brain death testing in this patient?
2. Describe the clinical examination for brain death determination.
3. How would you perform the apnea test?
4. What would you do if the apnea test could not be completed due to hypotension?

Model Answers:

1. Prerequisites (4 marks):

• Established cause: Severe TBI with neuroimaging confirmation (CT showing diffuse edema, loss of cisterns) (1)
• Irreversible injury: Neurosurgical assessment confirming no further intervention possible (0.5)
• Exclusion of confounders:
  • "Temperature: Core temperature ≥35°C (check) (0.5)"
  • "Drugs: Propofol/fentanyl ceased 24 hours ago (5 half-lives washout); rocuronium 8 hours ago (check train-of-four ratio greater than 0.9 or absence of neuromuscular blockade) (1)"
  • "Metabolic/endocrine: Exclude severe derangements (glucose 3-20 mmol/L, sodium 115-160 mmol/L, phosphate greater than 0.5 mmol/L) (0.5)"
  • "Shock: SBP ≥90-100 mmHg or MAP ≥60-65 mmHg (0.5)"

2. Clinical Examination (4 marks):

• Two qualified doctors: Intensivists, neurologists, or neurosurgeons; separate examinations (0.5)
• Motor response: Absent motor response to supraorbital pressure (0.5)
• Brainstem reflexes (all must be absent):
  • "Pupillary light reflex (CN II, III): Fixed pupils, no response to light (0.5)"
  • "Corneal reflex (CN V, VII): No blink to corneal stimulation (0.5)"
  • "Oculocephalic reflex (CN III, VI, VIII): Eyes move with head (contraindicated if C-spine injury) (0.5)"
  • "Oculovestibular reflex (CN III, VI, VIII): No eye movement to ice-cold water in ear canal (0.5)"
  • "Gag reflex (CN IX, X): No response to posterior pharyngeal stimulation (0.5)"
  • "Cough reflex (CN X): No cough to tracheal suctioning (0.5)"

3. Apnea Test (2 marks):

• Pre-oxygenate FiO2 1.0 for 10 minutes; adjust ventilation to normocapnia (PaCO2 35-45 mmHg); baseline ABG (0.5)
• Disconnect ventilator; provide apneic oxygenation (O2 6 L/min at carina via ETT) (0.5)
• Observe for respiratory effort for 8-10 minutes (0.5)
• Repeat ABG; positive test if PaCO2 ≥60 mmHg or ≥20 mmHg rise without respiratory effort (0.5)

4. Indeterminate Apnea Test (2 marks):

• If apnea test aborted due to hypotension (or other instability), proceed to ancillary testing (1)
• Options: EEG (electrocerebral silence), TCD (reverberating flow or absent diastolic flow), CTA (no intracranial filling), cerebral angiography (gold standard), or scintigraphy (hollow skull sign) (1)

---

Viva 2: Managing Cardiovascular Instability in a Potential Organ Donor

Scenario: A 45-year-old female with spontaneous intracerebral hemorrhage (ICH) has been declared brain dead 6 hours ago. The family has consented to organ donation. She is currently hypotensive (BP 75/40 mmHg) on noradrenaline 0.3 mcg/kg/min, with a heart rate of 50 bpm, urine output of 600 mL/hour, and serum sodium of 158 mmol/L.

Examiner Questions:

1. What are the likely causes of her hemodynamic instability and polyuria?
2. Outline your management approach.
3. What hormone replacement therapy would you consider?
4. What are the donor management goals (Rule of 100s)?

Model Answers:

1. Causes (3 marks):

• Hypotension:
  • Loss of sympathetic tone (brain death) → vasodilation (1)
  • Hypovolemia (diabetes insipidus with polyuria) (0.5)
  • Myocardial dysfunction (neurogenic myocardial stunning) (0.5)
• Polyuria:
  • Diabetes insipidus (loss of ADH secretion) → urine output greater than 4 mL/kg/h (0.5)
• Hypernatremia:
  • DI-induced free water loss (0.5)

2. Management Approach (4 marks):

• Fluid resuscitation: Hypotonic fluid (0.45% saline or 5% dextrose) to replace urinary losses; target euvolaemia (CVP 6-10 mmHg) (1)
• Vasopressin infusion: First-line vasopressor; start at 0.5-1 unit/h, titrate to MAP ≥65-80 mmHg; replaces ADH deficiency and provides vasoconstriction (1)
• Vasopressin for DI: Titrate to reduce urine output to 0.5-3 mL/kg/h (or consider DDAVP 1-4 mcg IV q6-12h) (0.5)
• Wean noradrenaline: As vasopressin takes effect, gradually wean noradrenaline (0.5)
• Treat bradycardia: If hemodynamically significant (unlikely at HR 50 unless low cardiac output), consider adrenaline infusion or temporary pacing (0.5)
• Echocardiography: TTE or TEE to assess LV function, volume status, regional wall motion abnormalities (0.5)

3. Hormone Replacement Therapy (2 marks):

• Methylprednisolone: 15 mg/kg IV once (up to 1 g); anti-inflammatory, reduces cytokine storm, improves lung function (0.5)
• Triiodothyronine (T3): 4 mcg IV bolus, then 3 mcg/h infusion; corrects hypothyroidism, improves cardiac contractility (0.5)
• Insulin: Variable-rate IV infusion to target glucose 4-10 mmol/L (0.5)
• Vasopressin: (already mentioned above for hemodynamics and DI) (0.5)

4. Rule of 100s (3 marks):

• MAP ≥65-80 mmHg (0.5)
• Heart rate 60-120 bpm (0.5)
• Urine output 0.5-3 mL/kg/h (or ~100 mL/h) (0.5)
• Hemoglobin ≥70-100 g/L (0.5)
• PaO2 ≥100 mmHg (13 kPa) on FiO2 ≤0.4 (0.5)
• Glucose 4-10 mmol/L (or below 10 mmol/L) (0.5)

---

References

1. Greer DM, Shemie SD, Lewis A, et al. Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death Project. JAMA. 2020;324(11):1078-1097. PMID: 32745229

2. Australian and New Zealand Intensive Care Society (ANZICS). The ANZICS Statement on Death and Organ Donation. Edition 4.1. 2021.

3. Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med. 2015;43(6):1291-1325. PMID: 25978154

4. Smith M. Brain death: time for an international consensus. Br J Anaesth. 2012;108 Suppl 1:i6-i9. PMID: 22194434

5. Australia and New Zealand Organ Donation Registry (ANZOD). Annual Report 2022. Adelaide: ANZDATA Registry, 2022.

6. Matesanz R, Domínguez-Gil B, Coll E, et al. Spanish experience as a leading country: what kind of measures were taken? Transpl Int. 2011;24(4):333-343. PMID: 21210865

7. Wijdicks EFM. The diagnosis of brain death. N Engl J Med. 2001;344(16):1215-1221. PMID: 11309638

8. Ducrocq X, Hassler D, Motte J, et al. Brain death and transcranial Doppler: experience in 130 cases of brain dead patients. J Neurol Sci. 1998;160(1):41-46. PMID: 9804117

9. Bittner HB, Kendall SW, Chen EP, et al. The effects of brain death on cardiopulmonary hemodynamics and pulmonary blood flow characteristics. Chest. 1995;108(5):1358-1363. PMID: 7587441

10. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation. 2003;75(8):1336-1341. PMID: 12717226

11. Avlonitis VS, Wigfield CH, Kirby JA, et al. The hemodynamic mechanisms of lung injury and systemic inflammatory response following brain death in the transplant donor. Am J Transplant. 2005;5(4 Pt 1):684-693. PMID: 15760392

12. Wood KE, Becker BN, McCartney JG, et al. Care of the potential organ donor. N Engl J Med. 2004;351(26):2730-2739. PMID: 15616210

13. Pratschke J, Wilhelm MJ, Kusaka M, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation. 1999;67(3):343-348. PMID: 10030278

14. Young GB, Shemie SD, Doig CJ, et al. Brief review: the role of ancillary tests in the neurological determination of death. Can J Anaesth. 2006;53(6):620-627. PMID: 16738298

15. Saposnik G, Bueri JA, Mauriño J, et al. Spontaneous and reflex movements in brain death. Neurology. 2000;54(1):221-223. PMID: 10636156

16. Datar S, Fugate J, Rabinstein A, et al. Completing the apnea test: decline in complications. Neurocrit Care. 2014;21(3):392-396. PMID: 24723148

17. Wijdicks EFM. The case against confirmatory tests for determining brain death in adults. Neurology. 2010;75(1):77-83. PMID: 20603488

18. American Clinical Neurophysiology Society. Guideline 3: Minimum Technical Standards for EEG Recording in Suspected Cerebral Death. J Clin Neurophysiol. 2006;23(2):97-104. PMID: 16612225

19. Hadani M, Bruk B, Ram Z, et al. Application of transcranial Doppler ultrasonography for the diagnosis of brain death. Intensive Care Med. 1999;25(8):822-828. PMID: 10447540

20. Monteiro LM, Bollen CW, van Huffelen AC, et al. Transcranial Doppler ultrasonography to confirm brain death: a meta-analysis. Intensive Care Med. 2006;32(12):1937-1944. PMID: 17019549

21. Bradac GB, Simon RS. Angiography in brain death. Neuroradiology. 1974;7(1):25-28. PMID: 4545802

22. Taylor T, Dineen RA, Gardiner DC, et al. Computed tomography (CT) angiography for confirmation of the clinical diagnosis of brain death. Cochrane Database Syst Rev. 2014;2014(3):CD009694. PMID: 24683046

23. Flowers WM Jr, Patel BR. Persistence of cerebral blood flow after brain death. South Med J. 2000;93(4):364-370. PMID: 10798500

24. Conrad GR, Sinha P. Scintigraphy as a confirmatory test of brain death. Semin Nucl Med. 2003;33(4):312-323. PMID: 14625841

25. Simpkin AL, Robertson LC, Barber VS, et al. Modifiable factors influencing relatives' decision to offer organ donation: systematic review. BMJ. 2009;338:b991. PMID: 19383730

26. Kootstra G, Daemen JH, Oomen AP. Categories of non-heart-beating donors. Transplant Proc. 1995;27(5):2893-2894. PMID: 7482956

27. The Transplantation Society of Australia and New Zealand (TSANZ). Clinical Guidelines for Organ Transplantation from Deceased Donors. Version 1.4. 2021.

28. Summers DM, Johnson RJ, Allen J, et al. Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet. 2010;376(9749):1303-1311. PMID: 20727576

29. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation. 2002;106(7):836-841. PMID: 12176956

30. Pennefather SH, Bullock RE, Mantle D, et al. Use of low dose arginine vasopressin to support brain-dead organ donors. Transplantation. 1995;59(1):58-62. PMID: 7839442

31. Schnuelle P, Berger S, de Boer J, et al. Effects of catecholamine application to brain-dead donors on graft survival in solid organ transplantation. Transplantation. 2001;72(3):455-463. PMID: 11502975

32. Mascia L, Pasero D, Slutsky AS, et al. Effect of a lung protective strategy for organ donors on eligibility and availability of lungs for transplantation: a randomized controlled trial. JAMA. 2010;304(23):2620-2627. PMID: 21156950

33. Novitzky D, Mi Z, Sun Q, et al. Thyroid hormone therapy in the management of 63,593 brain-dead organ donors: a retrospective analysis. Transplantation. 2014;98(10):1119-1127. PMID: 25083614

34. Opdam HI, Silvester W. Potential for organ donation in Victoria: an audit of hospital deaths. Med J Aust. 2006;185(5):250-254. PMID: 16948620

35. Howlett TA, Keogh AM, Perry L, et al. Anterior and posterior pituitary function in brain-stem-dead donors. Transplantation. 1989;47(5):828-834. PMID: 2655215

36. Blasi-Ibáñez A, Hirose R, Feiner J, et al. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesthesiology. 2009;110(2):333-341. PMID: 19194160

37. Franklin GA, Santos AP, Smith JW, et al. Optimization of donor management goals yields increased organ use. Am Surg. 2010;76(6):587-594. PMID: 20583513

38. Nakagawa TA, Ashwal S, Mathur M, et al. Guidelines for the determination of brain death in infants and children: an update of the 1987 Task Force recommendations. Pediatrics. 2011;128(3):e720-e740. PMID: 21873704

---

Last Updated: 24 January 2026
Author: MedVellum CICM Content Team
Evidence Review Date: January 2026
Next Review: January 2027

---

Document Information

• Lines: 1,574
• Citations: 38 PubMed references
• Target Audience: CICM Second Part candidates, ICU trainees, Intensivists
• Estimated Reading Time: 45 minutes
• Estimated Study Time: 3-4 hours (including SAQs and vivas)

---

This document is intended for educational purposes for medical professionals preparing for CICM examinations. It should not replace clinical guidelines or institutional protocols. Always refer to local protocols and consult senior colleagues for patient care decisions.